ClinicalTrials.gg
CompletedNCT04052828FETOUpdated Nov 4, 2026Results posted

Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)

An interventional study of FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) in Congenital Diaphragmatic Hernia, sponsored by Dr Erin Perrone. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Dr Erin Perrone · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Enrollment
34th of 36
4 · median 21
Started
2021
the only one that year
No phase
28 of 45
18 open now
Registered
24th of 45
by date
Lead sponsor
2 of 45
Dr Erin Perrone

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2021, is one of 28 with no phase, and was the 24th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

This is a single site pilot trial to assess the feasibility and safety of treating severe CDH with Fetal Endoscopic Tracheal Occlusion with the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) at Michigan Medicine. The study will enroll pregnant women that meet study criteria. Participants will have placement of FETO between gestational age at 27 weeks plus 0 days and 29 weeks 6 days. The timing for removal of FETO will ideally be between 34 weeks 0 days and 34 weeks and 6 days but ultimately decided by the Fetal Diagnosis and Treatment Center at Michigan Medicine.

This study requires that study participants live within 30 miles of the Von Voigtlander Women's Hospital and C.S. Mott Children's Hospital in order to maintain weekly follow up appointments while the balloon is in place and up to delivery. Additionally, there are lifestyle considerations where participants would be unable to carry on normal daily activities including exercise and sexual intercourse, not be able to work the remainder of the pregnancy, as well as have a support person that is available to stay with such as a spouse, friend, partner, parent.

Read the detailed description

This study has concluded and the second FETO trial (NCT07577414) has begun enrolling participants.

03

Conditions studied

  • Congenital Diaphragmatic Hernia

Keywords

  • pregnant
  • fetal endoscopic tracheal occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Singleton pregnancy
  • No pathogenic variants on microarray or pathologic findings on karyotype
  • Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects
  • Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as observed-to-expected (o/e) lung to head ratios (LHR) \<25% with liver up
  • Gestational age at FETO procedure: if o/e LHR \<25% will be done at 27 weeks plus 0 days to 29 weeks plus 6 days
  • Meets psychosocial criteria

    • Willing to reside within 30 minutes of Von Voigtlander Women's Hospital and ability to maintain follow up appointments
    • Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near Von Voigtlander Women's Hospital
    • Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work.

Exclusion criteria

Exclusion Criteria:

  • Multi-fetal pregnancy
  • History of latex allergy
  • History of preterm labor or incompetent cervix (requiring cerclage), short cervix (≤20mm), or uterine anomaly predisposing to preterm labor
  • Bilateral CDH, unilateral CDH with o/e LHR > 25%, or unilateral CDH with o/e LHR \<25% but liver completely down in abdomen
  • Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome
  • Maternal to elective fetoscopic surgery
  • Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery
  • Maternal isoimmunization or neonatal alloimmune thrombocytopenia
  • Maternal , with positive surface antigen, with presence of virus in maternal blood due to risk of fetal transmission during the procedure
  • No safe or feasible fetoscopic approach to balloon placement
  • Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    FETO with GOLDBAL2

    A balloon will be placed in the airway of the fetus during the FETO procedure.

    Device: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)

Interventions

  • DeviceFETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)

    This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation.

    Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.

    Time frame: Between 27 weeks 0 days and 29 week 6 days of gestation, within 1 week of enrollment

  2. Number of Participants With Successful Retrieval of the GOLDBAL2

    This will ideally occur around the 34th week of gestation and have the balloon removed prior to delivery. Alternatively, it could occur on placental bypass.

    Time frame: Removal prior to delivery approximately 34 weeks of gestation (up to approximately 8 weeks post enrollment) or at delivery on placental bypass (up to approximately 14 weeks post enrollment)

Secondary outcomes

  1. Change in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI)

    Fetal MRI done prior to balloon placement and again done at approximately 2 weeks of balloon retrieval. Observed to expected total fetal lung volume (o/e TFLV) is the percentage of lung volume a fetus has compared to the expected lung volume for a fetus at the same gestational age. It is calculated by dividing the observed TFLV by the expected TFLV and multiplying by 100 to get a percent. This outcome measure is the median change in o/e TFLV between the MRIs.

    Time frame: baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval (approximately 11 weeks post enrollment)

  2. Change in Fetal Lung Growth

    Fetal ultrasounds will be done weekly while the balloon is in place. Fetal lung growth will be calculated as the difference between the observed to expected Lung to Head Ratio (o/e LHR) pre-balloon placement and the o/e LHR immediately prior to balloon removal. O/e LHR uses the area of the lung opposite of the diaphragmatic hernia divided by head circumference to get a lung to head ratio. The observed to expected lung to head ratio is the lung to head ratio divided by the expected lung to head ratio at that gestational age multiplied by 100 to get a percent. This outcome measure describes the change in o/e LHR.

    Time frame: baseline (before balloon placement), immediately prior to balloon removal (up to approximately 14 weeks post enrollment)

  3. Gestational Age at Delivery

    Time frame: At the time of delivery (up to approximately 14 weeks post enrollment)

  4. Survival of Infant to Hospital Discharge or 180 Days After Hospitalized

    This will be measured after the infant is delivered to hospital discharge or analyzed for survival at 180 days for those still hospitalized at that time point.

    Time frame: Discharge from hospital or up to 180 days in the hospital (up to approximately 40 weeks post enrollment)

  5. Number of Participants With Maternal Complications

    Complications during pregnancy, and/or at delivery and follow-up to include; preterm labor, premature rupture of membranes (PROM), Preterm Premature Rupture of Membranes (PPROM), oligohydramnios, polyhydramnios, placental abruption, chorioamniotic separation, chorioamnionitis, and other infection. In results, patients who experience PPROM are also counted for PROM.

    Time frame: up to 4-8 weeks postpartum (up to approximately 22 weeks post enrollment)

07

Results

Posted Nov 4, 2026

Participant flow

Patients were recruited at the Fetal Diagnosis and Treatment Center at Michigan Medicine.

Participant flow — Overall Study
MilestoneFETO With GOLDBAL2
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation.

Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.

Time frame:
Between 27 weeks 0 days and 29 week 6 days of gestation, within 1 week of enrollment
Reported as:
Count of participants · Participants
Number of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation.
ParticipantsFETO With GOLDBAL2
Number of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation.4
PrimaryNumber of Participants With Successful Retrieval of the GOLDBAL2

This will ideally occur around the 34th week of gestation and have the balloon removed prior to delivery. Alternatively, it could occur on placental bypass.

Time frame:
Removal prior to delivery approximately 34 weeks of gestation (up to approximately 8 weeks post enrollment) or at delivery on placental bypass (up to approximately 14 weeks post enrollment)
Reported as:
Count of participants · Participants
Number of Participants With Successful Retrieval of the GOLDBAL2
ParticipantsFETO With GOLDBAL2
Successful Removal3
Not Successful Removal1
SecondaryChange in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI)

Fetal MRI done prior to balloon placement and again done at approximately 2 weeks of balloon retrieval. Observed to expected total fetal lung volume (o/e TFLV) is the percentage of lung volume a fetus has compared to the expected lung volume for a fetus at the same gestational age. It is calculated by dividing the observed TFLV by the expected TFLV and multiplying by 100 to get a percent. This outcome measure is the median change in o/e TFLV between the MRIs.

Time frame:
baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval (approximately 11 weeks post enrollment)
Reported as:
Median · percent of expected lung volume
Change in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI)
percent of expected lung volumeFETO With GOLDBAL2
Change in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI)13.75 (-3 to 31)
SecondaryChange in Fetal Lung Growth

Fetal ultrasounds will be done weekly while the balloon is in place. Fetal lung growth will be calculated as the difference between the observed to expected Lung to Head Ratio (o/e LHR) pre-balloon placement and the o/e LHR immediately prior to balloon removal. O/e LHR uses the area of the lung opposite of the diaphragmatic hernia divided by head circumference to get a lung to head ratio. The observed to expected lung to head ratio is the lung to head ratio divided by the expected lung to head ratio at that gestational age multiplied by 100 to get a percent. This outcome measure describes the change in o/e LHR.

Time frame:
baseline (before balloon placement), immediately prior to balloon removal (up to approximately 14 weeks post enrollment)
Reported as:
Median · percent of expected lung to head ratio
Change in Fetal Lung Growth
percent of expected lung to head ratioFETO With GOLDBAL2
Change in Fetal Lung Growth18.95 (8.6 to 24)
SecondaryGestational Age at Delivery
Time frame:
At the time of delivery (up to approximately 14 weeks post enrollment)
Reported as:
Median · weeks gestational age
Gestational Age at Delivery
weeks gestational ageFETO With GOLDBAL2
Gestational Age at Delivery33.857 (33.714 to 37.143)
SecondarySurvival of Infant to Hospital Discharge or 180 Days After Hospitalized

This will be measured after the infant is delivered to hospital discharge or analyzed for survival at 180 days for those still hospitalized at that time point.

Time frame:
Discharge from hospital or up to 180 days in the hospital (up to approximately 40 weeks post enrollment)
Reported as:
Count of participants · Participants
Survival of Infant to Hospital Discharge or 180 Days After Hospitalized
ParticipantsFETO With GOLDBAL2
Infant survived to discharge or 180 days in hospital1
Infant did not survive to discharge or 180 days in hospital3
SecondaryNumber of Participants With Maternal Complications

Complications during pregnancy, and/or at delivery and follow-up to include; preterm labor, premature rupture of membranes (PROM), Preterm Premature Rupture of Membranes (PPROM), oligohydramnios, polyhydramnios, placental abruption, chorioamniotic separation, chorioamnionitis, and other infection. In results, patients who experience PPROM are also counted for PROM.

Time frame:
up to 4-8 weeks postpartum (up to approximately 22 weeks post enrollment)
Reported as:
Count of participants · Participants
Number of Participants With Maternal Complications
ParticipantsFETO With GOLDBAL2
Preterm Labor — Patients who had this complication3
Preterm Labor — Patients who did not have this complication1
Premature Rupture of Membranes (PROM) — Patients who had this complication2
Premature Rupture of Membranes (PROM) — Patients who did not have this complication2
Preterm Premature Rupture of Membranes (PPROM) — Patients who had this complication2
Preterm Premature Rupture of Membranes (PPROM) — Patients who did not have this complication2
Oligohydramnios — Patients who had this complication2
Oligohydramnios — Patients who did not have this complication2
Polyhydramnios — Patients who had this complication2
Polyhydramnios — Patients who did not have this complication2
Placental Abruption — Patients who had this complication0
Placental Abruption — Patients who did not have this complication4
Chorioamniotic Separation — Patients who had this complication3
Chorioamniotic Separation — Patients who did not have this complication1
Chorioamnionitis — Patients who had this complication2
Chorioamnionitis — Patients who did not have this complication2
Other Infection — Patients who had this complication0
Other Infection — Patients who did not have this complication4

Adverse events

Collected over From enrollment to 30 days after delivery for fetus/baby. From enrollment to maternal follow up appointment at 4 to 8 weeks after delivery for mother (up to approximately 22 weeks post enrollment). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FETO With GOLDBAL2 - Mother0/4 (0%)3/4 (75%)4/4 (100%)
FETO With GOLDBAL2 - Fetus/Baby3/4 (75%)4/4 (100%)4/4 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventFETO With GOLDBAL2 - MotherFETO With GOLDBAL2 - Fetus/Baby
Respiratory failure and complications due to CDH with pulmonary hypoplasiaCongenital, familial and genetic disorders—4/4
CDH associated hemodynamic instabilityCongenital, familial and genetic disorders—4/4
hypoxemiaBlood and lymphatic system disorders—4/4
Preterm BirthGeneral disorders—3/4
pulmonary hypertension or hypertensive crisis requiring treatmentRespiratory, thoracic and mediastinal disorders—3/4
Preterm contractions requiring hospital admissionPregnancy, puerperium and perinatal conditions2/4—
Use of ECMO and associated complicationsSurgical and medical procedures—2/4
C-section for non-reassuring fetal heart tones leading to preterm deliverySurgical and medical procedures1/4—
Cholelithiasis with gallbladder attacksGastrointestinal disorders1/4—
Mother reported decreased fetal movementPregnancy, puerperium and perinatal conditions—1/4
Most frequent other events
Showing 10 of 36
Most frequent other events
EventFETO With GOLDBAL2 - MotherFETO With GOLDBAL2 - Fetus/Baby
discomfort or skin separation at incision siteSurgical and medical procedures4/4—
uterine irritability abdominal pain, cramping, and/or contractionsPregnancy, puerperium and perinatal conditions4/4—
nausea with or without vomitingGeneral disorders4/4—
general CDH expected symptoms and comorbidities within the first 30 days of lifeCongenital, familial and genetic disorders—4/4
headacheGeneral disorders3/4—
amnioreductionSurgical and medical procedures3/4—
new ECHO anatomic findingCardiac disorders—3/4
epidural related symptoms including tenderness, pain, scant heme, and/or replacementSurgical and medical procedures2/4—
yeast infectionPregnancy, puerperium and perinatal conditions2/4—
incisional pain at c-section site with or without redness/tendernessPregnancy, puerperium and perinatal conditions2/4—

Baseline characteristics

4 participants enrolled with their fetuses. Each participant was carrying one fetus for a total of 8 participants analyzed.

Age, Customized
Age, Customized(Participants)FETO With GOLDBAL2
Participants aged 18 years and older4
Sex/Gender, Customized
Sex/Gender, Customized(Participants)FETO With GOLDBAL2
Sex of Pregnant Participant — Female4
Sex of Pregnant Participant — Male0
Sex of Fetus — Female0
Sex of Fetus — Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FETO With GOLDBAL2
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White3
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FETO With GOLDBAL2
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Observed to Expected Total Fetal Lung Volume (o/e TFLV)
Observed to Expected Total Fetal Lung Volume (o/e TFLV)(percent of expected lung volume)FETO With GOLDBAL2
Median20.75 (17 to 24)
Observed to Expected Lung to Head Ratio (o/e LHR)
Observed to Expected Lung to Head Ratio (o/e LHR)(percent of expected lung to head ratio)FETO With GOLDBAL2
Median20.5 (14.6 to 22)
08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2025, 52 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion. A results delay was requested in May 2025.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's 52 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 12, 2019
StartActual
Apr 5, 2021
Primary completionActual
Aug 12, 2025
CompletionActual
Oct 16, 2025
Results delay requested
May 23, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of successful placementsParticipants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at gestational ageGestational Age 27 weeks zero daysWeeks Zero Days (27w0d) to 29 weeksWeeks and 6 daysDays (29w6d) gestationGestation.Time frame: 27w0d - 29w6d → Between 27 weeks 0 days and 29 week 6 days of gestation, within 1 week of enrollment
  • EditedNumber of successful retrievalsParticipants With Successful Retrieval of the GOLDBAL2Time frame: Removal prior to delivery approximately 34 weeks of gestation → Removal prior to delivery approximately 34 weeks of gestation (up to approximately 8 weeks post enrollment) or at delivery on placental bypass (up to approximately 14 weeks post enrollment)
Nov 4, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedChange in observedObserved to expected total fetal lung to head ratiosExpected Total Fetal Lung Volume (o/e TFLV) on prenatal magnetic resonance imagingPrenatal Magnetic Resonance Imaging (MRI)Time frame: baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval → baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval (approximately 11 weeks post enrollment)
  • EditedChange in fetal lung growthFetal Lung GrowthTime frame: baseline (before balloon placement), immediately prior to balloon retrieval → baseline (before balloon placement), immediately prior to balloon removal (up to approximately 14 weeks post enrollment)
  • EditedGestational ageAge at deliveryDeliveryTime frame: At the time of delivery (up to approximately 34 weeks) → At the time of delivery (up to approximately 14 weeks post enrollment)
  • EditedSurvival of infantInfant to hospital dischargeHospital Discharge or 180 days after hospitalizedDays After HospitalizedTime frame: Discharge from hospital or up to 180 days in the hospital → Discharge from hospital or up to 180 days in the hospital (up to approximately 40 weeks post enrollment)
  • EditedNumber of maternal complicationsParticipants With Maternal ComplicationsTime frame: up to 4-6 weeks postpartum → up to 4-8 weeks postpartum (up to approximately 22 weeks post enrollment)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of successful placementsParticipants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at gestational ageGestational Age 27 weeks zero daysWeeks Zero Days (27w0d) to 29 weeksWeeks and 6 daysDays (29w6d) gestationGestation.Time frame: 27w0d - 29w6d → Between 27 weeks 0 days and 29 week 6 days of gestation, within 1 week of enrollment
    • EditedNumber of successful retrievalsParticipants With Successful Retrieval of the GOLDBAL2Time frame: Removal prior to delivery approximately 34 weeks of gestation → Removal prior to delivery approximately 34 weeks of gestation (up to approximately 8 weeks post enrollment) or at delivery on placental bypass (up to approximately 14 weeks post enrollment)
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedChange in observedObserved to expected total fetal lung to head ratiosExpected Total Fetal Lung Volume (o/e TFLV) on prenatal magnetic resonance imagingPrenatal Magnetic Resonance Imaging (MRI)Time frame: baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval → baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval (approximately 11 weeks post enrollment)
    • EditedChange in fetal lung growthFetal Lung GrowthTime frame: baseline (before balloon placement), immediately prior to balloon retrieval → baseline (before balloon placement), immediately prior to balloon removal (up to approximately 14 weeks post enrollment)
    • EditedGestational ageAge at deliveryDeliveryTime frame: At the time of delivery (up to approximately 34 weeks) → At the time of delivery (up to approximately 14 weeks post enrollment)
    • EditedSurvival of infantInfant to hospital dischargeHospital Discharge or 180 days after hospitalizedDays After HospitalizedTime frame: Discharge from hospital or up to 180 days in the hospital → Discharge from hospital or up to 180 days in the hospital (up to approximately 40 weeks post enrollment)
    • EditedNumber of maternal complicationsParticipants With Maternal ComplicationsTime frame: up to 4-6 weeks postpartum → up to 4-8 weeks postpartum (up to approximately 22 weeks post enrollment)
    + 4 other changes: index terms, verification date, registry dates and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04052828
Lead sponsor
Dr Erin Perrone
Responsible party
Dr Erin Perrone (Associate Professor of Surgery, University of Michigan) — Sponsor-investigator
First posted
Aug 12, 2019
Start date
Apr 5, 2021
Primary completion
Aug 12, 2025
Completion
Oct 16, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Erin Perrone, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion